Co-Authors
This is a "connection" page, showing publications co-authored by Zdzislaw Szulc and Aiping Bai.
Connection Strength
0.693
-
Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase. PLoS One. 2017; 12(6):e0177805.
Score: 0.155
-
Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs. Bioorg Med Chem. 2014 Dec 15; 22(24):6933-44.
Score: 0.129
-
Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells. Bioorg Med Chem. 2010 Nov 01; 18(21):7565-79.
Score: 0.097
-
Synthesis and bioevaluation of omega-N-amino analogs of B13. Bioorg Med Chem. 2009 Mar 01; 17(5):1840-8.
Score: 0.087
-
Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents. Bioorg Med Chem. 2008 Jan 15; 16(2):1015-31.
Score: 0.079
-
Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis. Cytokine. 2020 11; 135:155219.
Score: 0.048
-
Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. Cancer Res. 2017 12 15; 77(24):6950-6962.
Score: 0.040
-
Novel sphingosine kinase-1 inhibitor, LCL351, reduces immune responses in murine DSS-induced colitis. Prostaglandins Other Lipid Mediat. 2017 05; 130:47-56.
Score: 0.038
-
Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg Med Chem. 2008 Jan 15; 16(2):1032-45.
Score: 0.020